Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

Main Article Content

Eric Simpson
Andrew Blauvelt
Emma Guttman-Yassky
Margitta Worm
Charles Lynde
Hidehisa Saeki
Yves Poulin
Andreas Wollenberg

Keywords

Atopic Dermatitis, Biologic, Safety, Efficacy, Tralokinumab

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Boguniewicz M, Leung DY. Immunol Rev 2011; 242: 233–246.

3. Guttman-Yassky E et al. Semin Cutan Med Surg 2017; 36: 100–103.

4. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.

5. Popovic B et al. J Mol Biol 2017; 429: 208–219.

6. Furue K et al. Immunology 2019; 158: 281–286.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489. 8. Bieber T. Allergy 2020; 75: 54–62.